entertainment -WSS

entertainment

author：fashion 2025-09-06 09:57:11 - browse：376

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Lab trade group sues FDA to halt regulation of lab

WSS

Akili, maker of video game for ADHD, to be acquired for 34 million

Listen: Your guide to Wegovy's blockbuster heart study

Large hospital system sues Multiplan for low

Some of the ways extreme heat will change life as we know it

Stigma and the return of syphilis

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

entertainment

entertainment

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Maui funeral service workers on devastation of fires: 'I'm in shock'

At least 13 dead in Texas as scorching temps continue

After John Oliver segment, STAT readers share their opioid

Novavax promises a turnaround & Lilly roils the obesity market

White House drug shortages task force keeps mum with Congress

How one medical school became remarkably diverse

After John Oliver segment, STAT readers share their opioid

Drug repurposing or repositioning? The language matters

Health insurers say they are turning to AI to cut costs, improve care

leisure time

Do more moles mean more problems? Not so, says new study

Startling documents reveal new facets of Sacklers' opioid empire

https://cbu01.alicdn.com/img/ibank/2016/133/266/3082662331_1882814993.220x220xz.jpg

An innovative path out of biotech’s “valley of death”

Timeline: Special counsel's investigation into Trump's handling of classified documents

Focused ultrasound for uterine fibroids: an uphill battle

leisure time

entertainment

knowledge

knowledge